INTERVENTION 1:	Intervention	0
1mg/kg q2w	Intervention	1
Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w	Intervention	2
INTERVENTION 2:	Intervention	3
3mg/kg q2w	Intervention	4
Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w	Intervention	5
Inclusion Criteria:	Eligibility	0
Written informed consent must have been obtained prior to any screening procedures	Eligibility	1
Phase I part: Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1 (refer to Appendix 1), who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists.	Eligibility	2
disease	DOID:4,OGMS:0000031	96-103
Phase II part: Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have progressed following their last prior therapy, and fit into one of the following groups:	Eligibility	3
Group 1a and 1b: NSCLC:	Eligibility	4
group	CHEBI:24433	0-5
Patients with NSCLC must have had disease recurrence or progression during or after no more than one prior systemic chemotherapy regimen (platinum doublet-based) for advanced or metastatic disease. Prior maintenance therapy is allowed (e.g. pemetrexed, erlotinib, bevacizumab).	Eligibility	5
disease	DOID:4,OGMS:0000031	34-41
disease	DOID:4,OGMS:0000031	189-196
platinum	CHEBI:33364	138-146
pemetrexed	CHEBI:63616	241-251
erlotinib	CHEBI:114785	253-262
Only patients with EGFR mutation-negative tumor are eligible (defined as negative for exon 19 deletions and for the L858R mutation in EGFR at a minimum; however, if more extensive EGFR mutation testing has been performed, the tumor must not harbor any known activating EGFR mutations in Exons 18-21 in order to be considered EGFR mutation-negative). All patients must be tested for EGFR mutational status and, for ALK translocation status if no mutation is detected in EGFR. Patients with ALK translocation-positive NSCLC must have had disease progression following treatment with a corresponding inhibitor and no more than one systemic chemotherapy regimen (platinum doublet-based), in any sequence.	Eligibility	6
disease	DOID:4,OGMS:0000031	536-543
inhibitor	CHEBI:35222	597-606
platinum	CHEBI:33364	659-667
Group 2: Melanoma:	Eligibility	7
group	CHEBI:24433	0-5
melanoma	HP:0002861,DOID:1909	9-17
All patients must have been tested for BRAF mutations. Patients with V600 mutation positive melanoma must have clinical or radiological evidence of disease progression during or after treatment with a BRAF inhibitor alone or in combination with other agents.	Eligibility	8
melanoma	HP:0002861,DOID:1909	92-100
disease	DOID:4,OGMS:0000031	148-155
inhibitor	CHEBI:35222	206-215
Group 3: Triple negatice breast cancer.	Eligibility	9
group	CHEBI:24433	0-5
breast cancer	DOID:1612	25-38
Group 4: Anaplastic thyroid cancer	Eligibility	10
group	CHEBI:24433	0-5
cancer	DOID:162	28-34
Patients are not required to have received or progressed on a prior therapy.	Eligibility	11
Patients must not be at short term risk for life threatening complications (such as airway compromise or bleeding from locoregional or metastatic disease).	Eligibility	12
disease	DOID:4,OGMS:0000031	146-153
Chemoradiation and/or surgery should be considered prior to study entry for those patients with locally advanced disease if those therapies are considered to be in the best interest of the patient.	Eligibility	13
surgery	OAE:0000067	22-29
disease	DOID:4,OGMS:0000031	113-120
patient	HADO:0000008,OAE:0001817	82-89
patient	HADO:0000008,OAE:0001817	189-196
ECOG Performance Status  1.	Eligibility	14
Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy. Patient must be willing to undergo a new tumor biopsy at baseline or at molecular pre-screening if applicable, and during therapy on this study. For patients in the phase II part of the study, exceptions may be granted after documented discussion with Novartis. After a sufficient number of paired biopsies are collected, the decision may be taken to stop the collection of biopsies.	Eligibility	15
site	BFO:0000029	21-25
disease	DOID:4,OGMS:0000031	29-36
patient	HADO:0000008,OAE:0001817	0-7
patient	HADO:0000008,OAE:0001817	94-101
patient	HADO:0000008,OAE:0001817	243-250
part of	BAO:0090002,BFO:0000050	268-275
Exclusion Criteria:	Eligibility	16
History of severe hypersensitivity reactions to other mAbs	Eligibility	17
history	BFO:0000182	0-7
severe	HP:0012828	11-17
hypersensitivity	GO:0002524,DOID:1205	18-34
Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.	Eligibility	18
active	PATO:0002354	14-20
autoimmune disease	DOID:417	41-59
vitiligo	HP:0001045,DOID:12306	75-83
type i diabetes mellitus	HP:0100651	85-109
hypothyroidism	HP:0000821,DOID:1459	120-134
condition	PDRO:0000129	153-162
condition	PDRO:0000129	246-255
hormone	CHEBI:24621	178-185
psoriasis	DOID:8893	199-208
Active infection requiring systemic antibiotic therapy.	Eligibility	19
active	PATO:0002354	0-6
HIV infection.	Eligibility	20
Active HBV or HCV infection.	Eligibility	21
active	PATO:0002354	0-6
Patients with ocular melanoma.	Eligibility	22
ocular melanoma	DOID:1752	14-29
Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 weeks washout period. For patients receiving anticancer immunotherapies such as CTLA-4 antagonists, 6 weeks is indicated as the washout period.	Eligibility	23
mitomycin c	CHEBI:27504	142-153
Prior PD-1- or PD-L1-directed therapy.	Eligibility	24
Patients requiring chronic treatment with systemic steroid therapy, other than replacement-dose steroids in the setting of adrenal insufficiency. Topical, inhaled, nasal and ophthalmic steroids are not prohibited.	Eligibility	25
chronic	HP:0011010	19-26
steroid	CHEBI:35341	51-58
steroid	CHEBI:35341	96-103
steroid	CHEBI:35341	185-192
adrenal insufficiency	HP:0000846	123-144
Patients receiving systemic treatment with any immunosuppressive medication (other than steroids as described above).	Eligibility	26
Use of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.	Eligibility	27
influenza	DOID:8469	54-63
Presence of  CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if  CTCAE grade 3) due to prior cancer therapy	Eligibility	28
alopecia	HP:0001596,DOID:987	44-52
peripheral neuropathy	HP:0009830,DOID:870	54-75
excluded	HP:0040285	103-111
cancer	DOID:162	144-150
Outcome Measurement:	Results	0
Phase l: The Exposure (AUC(0-336h)) After First Dose of Treatment at Cycle 3 (Each Cycle = 28 Days)	Results	1
auc	BAO:0002120	23-26
Estimated the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD) for PDR001.	Results	2
mtd	BAO:0001248	81-84
AUC0-336h is the AUC from time zero to 336 hour post dose of a measurable concentration sampling time.	Results	3
auc	BAO:0002120	0-3
auc	BAO:0002120	17-20
time	PATO:0000165	26-30
time	PATO:0000165	97-101
hour	UO:0000032	43-47
Time frame: Predose, 1hour (h), 24h, 48h, 72h, 168h, 240h, 336h post dose (cycle 3)	Results	4
time	PATO:0000165	0-4
Results 1:	Results	5
Arm/Group Title: 1mg/kg q2w	Results	6
Arm/Group Description: Phase I Dose escalation cohort patients who took PDR001 1 mg/kg q2w	Results	7
Overall Number of Participants Analyzed: 8	Results	8
Geometric Mean (Geometric Coefficient of Variation)	Results	9
mean	BAO:0002173	10-14
coefficient of variation	BAO:0000531	26-50
Unit of Measure: day*ug/mL  270        (52.5%)	Results	10
day	UO:0000033	17-20
Results 2:	Results	11
Arm/Group Title: 3mg/kg q2w	Results	12
Arm/Group Description: Phase I Dose escalation cohort patients who took PRD001 3 mg/kg q2w	Results	13
Overall Number of Participants Analyzed: 4	Results	14
Geometric Mean (Geometric Coefficient of Variation)	Results	15
mean	BAO:0002173	10-14
coefficient of variation	BAO:0000531	26-50
Unit of Measure: day*ug/mL  1150        (51.1%)	Results	16
day	UO:0000033	17-20
Adverse Events 1:	Adverse Events	0
Total: 9/16 (56.25%)	Adverse Events	1
Anaemia 2/16 (12.50%)	Adverse Events	2
Lymphadenopathy 0/16 (0.00%)	Adverse Events	3
lymphadenopathy	HP:0002716	0-15
Thrombocytopenia 0/16 (0.00%)	Adverse Events	4
thrombocytopenia	HP:0001873,DOID:1588	0-16
Acute coronary syndrome 0/16 (0.00%)	Adverse Events	5
acute coronary syndrome	HP:0033678	0-23
Acute myocardial infarction 0/16 (0.00%)	Adverse Events	6
acute myocardial infarction	DOID:9408	0-27
Arrhythmia 0/16 (0.00%)	Adverse Events	7
arrhythmia	HP:0011675	0-10
Atrial fibrillation 0/16 (0.00%)	Adverse Events	8
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Atrial flutter 0/16 (0.00%)	Adverse Events	9
atrial flutter	HP:0004749	0-14
Cardiac arrest 0/16 (0.00%)	Adverse Events	10
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
Cardiac tamponade 0/16 (0.00%)	Adverse Events	11
cardiac tamponade	HP:0033415,DOID:115	0-17
Coronary artery stenosis 0/16 (0.00%)	Adverse Events	12
coronary artery stenosis	HP:0005145	0-24
Adverse Events 2:	Adverse Events	13
Total: 7/15 (46.67%)	Adverse Events	14
Anaemia 0/15 (0.00%)	Adverse Events	15
Lymphadenopathy 0/15 (0.00%)	Adverse Events	16
lymphadenopathy	HP:0002716	0-15
Thrombocytopenia 1/15 (6.67%)	Adverse Events	17
thrombocytopenia	HP:0001873,DOID:1588	0-16
Acute coronary syndrome 0/15 (0.00%)	Adverse Events	18
acute coronary syndrome	HP:0033678	0-23
Acute myocardial infarction 0/15 (0.00%)	Adverse Events	19
acute myocardial infarction	DOID:9408	0-27
Arrhythmia 0/15 (0.00%)	Adverse Events	20
arrhythmia	HP:0011675	0-10
Atrial fibrillation 0/15 (0.00%)	Adverse Events	21
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Atrial flutter 0/15 (0.00%)	Adverse Events	22
atrial flutter	HP:0004749	0-14
Cardiac arrest 0/15 (0.00%)	Adverse Events	23
cardiac arrest	HP:0001695,DOID:0060319,OAE:0000461	0-14
Cardiac tamponade 0/15 (0.00%)	Adverse Events	24
cardiac tamponade	HP:0033415,DOID:115	0-17
Coronary artery stenosis 0/15 (0.00%)	Adverse Events	25
coronary artery stenosis	HP:0005145	0-24
